


<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>   <b>(PTO-1449)</b>				ATTY. DOCKET NO. 102258.288US5		SERIAL NO. 10/824,607	
				APPLICANT Jay N. COHN et al.			
				FILING DATE April 15, 2004		GROUP 1614	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	<del>Levine, Barry T. et al. September 1998. "Paradoxical Hypertension after Reversal of Heart Failure in Patients Treated with Intensive Vasodilator Therapy." <i>American Journal of Hypertension</i>, Vol. 11, No. 9. pp. 1041-1047.</del>						
/D.S./	Harjai, Kishore J. et al. February 1999. "Does Patient Race Influence Utilization of Effective Medical Therapy for Heart Failure?" <i>Journal of the American College of Cardiology</i> , Vol. 33, No. 2, Supplement A. pp. 179A.						
/D.S./	25 June 2004. Supplementary European Search Report from European Patent Application No. 00961745.7.						
EXAMINER <b>Darryl C. Sutton</b> <small>Digitally signed by Darryl C. Sutton DN: cn=Darryl C. Sutton, o=US, ou=USPTO, email=darryl.sutton@uspto.gov Date: 2007.09.12 15:32:02 -0400</small>				DATE CONSIDERED <b>09/12/2007</b>			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Application Number	10/824,607
Filing Date	04/15/2004
First Named Inventor	COHN et al.
Art. Unit	1614
Examiner Name	Darryl To Be Assigned Sutton
Attorney Docket Number	102258.288US5

[illegible][illegible]

Examiner Signature	Darryl C. Sutton	Digitally signed by Darryl C. Sutton DN: cn=Darryl C. Sutton, c=US, o=USPTO, email=darryl.sutton@uspto.gov Date: 2007.09.12 15:19:46 -0400	Date Considered	09/12/2007
-----------------------	------------------	--	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.***

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)  Sheet <u>2</u> of <u>3</u>		<b>Complete If Known</b>	
		Application Number	10/824,607
		Filing Date	04/15/2004
		First Named Inventor	COHN et al.
		Art Unit	1614
		Examiner Name	Darryl To Be Assigned Sutton
		Attorney Docket Number	102258.288US5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/D.S./	AA	FRANCIOSA, Joseph A., "African-American Heart Failure Trial (A-HeFT): Rationale, Design, and Methodology," Journal of Cardiac Failure, Vol. 8, No. 3, 2002, pp. 128-135	
/D.S./	AB	YANCY, Clyde W., et al., "Race and the Response to Adrenergic Blockage with Carvedilol in Patients with Chronic Heart Failure," N. Engl. J. Med., Vol. 344, No. 18, May 3, 2001, pp. 1358-1365	
/D.S./	AC	YANCY, Clyde W., "Heart Failure in African Americans: A Cardiovascular Enigma," Journal of Cardiac Failure, Vol. 6, No. 3, 2000, pp. 183-186	
/D.S./	AD	EXNER, Derek V., et al., "Lesser Response to Angiotensin-Converting-Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction," N. Engl. J. Med., Vol. 344, No. 18, May 3, 2001, pp. 1351-1357	
/D.S./	AE	PACKER, Milton, et al., "Effect of Carvedilol on Survival in Severe Chronic Heart Failure," N. Engl. J. Med., Vol. 344, No. 22, May 31, 2001, pp. 1651-1658	
/D.S./	AF	"A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure," N. Engl. J. Med., Vol. 344, No. 22, May 31, 2001, pp. 1659-1667	
/D.S./	AG	BRAUNWALD, Eugene, "Expanding Indications for Beta-Blockers in Heart Failure," N. Engl. J. Med., Vol. 344, No. 22, May 31, 2001, pp. 1711-1712	
/D.S./	AH	SCHWARTZ, Robert S., "Racial Profiling in Medical Research," N. Engl. J. Med., Vol. 344, No. 18, May 3, 2001, pp. 1392-1393	
/D.S./	AI	LEVINE, T. Barry, "Paradoxical Hypertension after Reversal of Heart Failure in Patients Treated with Intensive Vasodilator Therapy," American Journal of Hypertension, Ltd., 1998; 11:1041-1047	
/D.S./	AJ	ABSTRACTS - Heart Failure 179A, JACC, February 1999	

Examiner Signature	Darryl C. Sutton	Digitally signed by Darryl C. Sutton DN: cn=Darryl C. Sutton, o=US, email=darryl.sutton@uspto.gov Date: 2007.09.12 15:20:17 -0400	Date Considered	09/12/2007
--------------------	------------------	---	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/824,607
		Filing Date	04/15/2004
		First Named Inventor	COHN et al.
		Art Unit	1614
		Examiner Name	Darryl To Be Assigned Sutton
Sheet 3 of 3	Attorney Docket Number	102258.288US5	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/D.S./	AK	KAHN, Jonathan, "How a Drug Becomes "Ethnic": Law, Commerce, and the Production of Racial Categories in Medicine," Yale Journal of Health Policy, Law, and Ethics IV:1 (2004), pp. 1-46	
/D.S./	AL	PARKER, John D., et al., "The Effect of Hydralazine on the Development of Tolerance to Continuous Nitroglycerin," The Journal of Pharmacology and Experimental Therapeutics, Vol. 280, No. 2, pp. 866-875	
/D.S./	AM	KALINOWSKI, Leszek, et al., "Race-Specific Differences in Endothelial Function - Predisposition of African Americans to Vascular Diseases," Circulation, June 1, 2004, pp. 2511-2517	

Examiner Signature	Darryl C. Sutton	Digitally signed by Darryl C. Sutton DN: cn=Darryl C. Sutton, c=US, o=USPTO, email=Darryl.Sutton@uspto.gov Date: 2007.09.12 15:20:57 -04'00'	Date Considered	09/12/2007
--------------------	------------------	--	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



**INFORMATION DISCLOSURE  
CITATION IN AN  
APPLICATION**

(PTO-1449)

ATTY. DOCKET NO.  
102258.288US5

SERIAL NO.  
10/824,607

APPLICANT  
Jay N. COHN et al.

FILING DATE  
April 15, 2004

GROUP  
1614

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/D.S./	4,293,565	10/06/81	Cordes et al.			10/09/79
/D.S./	4,584,315	04/22/86	Marshall			12/13/83
/D.S./	6,458,797	10/01/02	Adams et al.			06/12/01
/D.S./	US 2004/0063719	04/01/04	Adams et al.			05/02/03

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
/D.S./	09059152	03/04/97	Japan			X	
/D.S./	EP 0 968 713 A1	05/11/98	Europe			X	

**OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)**

21 June 2004. Supplementary Partial European Search Report for EP 00 97 6651.0.

EXAMINER

Darryl C. Sutton

Digitally signed by Darryl C. Sutton  
DN: cn=Darryl C. Sutton, c=US, e=USPTO,  
email=darryl.sutton@uspto.gov  
Date: 2007.09.12 16:04:09 -04'00'

DATE CONSIDERED

09/12/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449/PTO  <h2 style="margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="margin: 0;">(Use as many sheets as necessary)</p>		<b>Complete if Known</b>  <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td style="width: 50%;">10/824600</td> </tr> <tr> <td>Filing Date</td> <td>15.2.2002</td> </tr> <tr> <td>First Named Inventor</td> <td>Cohn</td> </tr> <tr> <td>Art Unit</td> <td></td> </tr> <tr> <td>Examiner Name</td> <td>Daryl Sutton</td> </tr> <tr> <td>Attorney Docket Number</td> <td>102258288</td> </tr> </table>		Application Number	10/824600	Filing Date	15.2.2002	First Named Inventor	Cohn	Art Unit		Examiner Name	Daryl Sutton	Attorney Docket Number	102258288
Application Number	10/824600														
Filing Date	15.2.2002														
First Named Inventor	Cohn														
Art Unit															
Examiner Name	Daryl Sutton														
Attorney Docket Number	102258288														
Sheet 1	of 7														

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> Number <sup>4</sup> Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
/D.S./		WO 02/34303 A1	05-02-2002	Loscalzo et al		
/D.S./		WO 01/35961 A1	05-25-2001	Loscalzo et al		

[illegible]

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Please type a plus sign (+) inside this box ☐



PTO/SB/08B (10-86)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			<b>Complete If Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	10/824607	
			Filing Date		
			First Named Inventor	Cohn	
			Group Art Unit		
			Examiner Name	Darryl Sutton	
Sheet	2	of	7	Attorney Docket Number	102258.288

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/D.S./		Johnson, Clinical Pharmacy, Vol. 5, pages 536 and 541 (1986).	
/D.S./		Massie et al, Br. Heart J., 45:376-384 (1981).	
/D.S./		Turner et al, The American Journal of Cardiology, 47:910-916 (1981).	
/D.S./		Massie et al, Circulation, 63(3):658-664 (1981).	
/D.S./		Nelson et al, Journal of Cardiovascular Pharmacology, 5(4):574-579 (1983).	
/D.S./		Leier et al, Circulation, 63(1):102-109 (1981).	
/D.S./		Wilson et al, The American Journal of Medicine, 71:627-633 (1981).	
/D.S./		Biddle et al, J. Clin. Pharmacol., 21:343-350 (1981).	
/D.S./		Magorien et al, Clinical Research, 27(4):A617 (1979).	
/D.S./		Turner et al, Clinical Research, 29(2):246A (1981).	
/D.S./		Hibiya et al, Japanese Circulation Journal, 45:966 (Abstract No. 338) (1981).	

Examiner Signature	Darryl C. Sutton	Digitally signed by Darryl C. Sutton DN: cn=Darryl C. Sutton, c=US, o=USPTO, email=darryl.sutton@uspto.gov Date: 2007.09.12 15:57:24 -0400	Date Considered	09/12/2007
--------------------	------------------	---	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/088 (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	2010-10/824607
			Filing Date	08/07/2010
			First Named Inventor	Cohn
			Group Art Unit	
			Examiner Name	Darryl Sutton
Sheet 3 of 7	Attorney Docket Number	102258.288 US		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>2</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/D.S./		Franciosa et al, Circulation, 59(6):1085-1091 (1979).	
/D.S./		Lanas et al, Rev. Med. Chile, 107:926-930 (1979).	
/D.S./		Usdin et al, Coeur, 10(1):119-128 (1979).	
/D.S./		Burnier et al, Hypertension, 22(3):339-347 (1993).	
/D.S./		von Lutterotti et al, American Journal of Hypertension, 4(4 Part 2):346S-349S (1991).	

Examiner Signature	Darryl C. Sutton	<small>Digitally signed by Darryl C. Sutton DN: cn=Darryl C. Sutton, o=US, ou=USPTO, email=darryl.sutton@uspto.gov Date: 2007.09.12 15:57:51 -0400</small>	Date Considered	09/12/2007
-----------------------	------------------	--	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





+

[illegible][illegible]

Examiner Signature	Darryl C. Sutton Digitally signed by Darryl C. Sutton DN: cn=Darryl C. Sutton, o=US, ou=USPTO, email=darryl.sutton@uspto.gov Date: 2007.09.12 15:58:15 -0400	Date Considered	09/12/2007
-----------------------	---	--------------------	------------

+

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>Complete If Known</b>		
			Application Number	10/824607	
			Filing Date	2 30 3, 2002	
			First Named Inventor	Cohn	
			Group Art Unit		
			Examiner Name	Darryl Sutton	
			Attorney Docket Number	102258.288	
Sheet	5	of	7		

[illegible][illegible]

Examiner Signature	Darryl C. Sutton Digitally signed by Darryl C. Sutton DN: cn=Darryl C. Sutton, c=US, o=USPTO, email=darryl.sutton@uspto.gov Date: 2007.09.12 15:58:39 -0400	Date Considered	09/12/2007
-----------------------	---	--------------------	------------

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

+

Please type a plus sign (+) inside this box



PTO/SB/088 (10-96)  
Approved for use through 10/31/99. OMB 0851-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/824607
		Filing Date	
		First Named Inventor	Cohn
		Group Art Unit	
		Examiner Name	Darryl Sutton
Sheet 6 of 7	Attorney Docket Number	102258.288	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/D.S./		Cohn et al, The New England Journal of Medicine, 325(5):303-310 (1991).	
/D.S./		Cohn et al, The New England Journal of Medicine, 314(24):1547-1552 (1986).	
/D.S./		Carson et al, Circulation, Supplement I, 92(8):I31-I32, Abstract No. 0145 (1995).	
/D.S./		Francis et al, Circulation, Supplement VI, 87(6):VI40-VI48 (1993).	
/D.S./		Pierpont et al, Chest, 73(1):8-13 (1978).	
/D.S./		Massie et al, The American Journal of Cardiology, 40:794-801 (1977).	
/D.S./		Kaplan et al, Annals of Internal Medicine, 84:639-645 (1976).	
/D.S./		Bauer et al, Circulation, 84(1):35-39 (1991).	
/D.S./		The SOLVD Investigators, The New England Journal of Medicine, 327(10):685-691 (1992).	
/D.S./		Ziesche et al, Circulation, 87(6):VI56-VI64 (1993).	
/D.S./		Rector et al, Circulation, 87(6):VI71-VI77 (1993).	

Examiner Signature	Darryl C. Sutton	Digitally signed by Darryl C. Sutton DN: cn=Darryl C. Sutton, c=US, o=USPTO, email=darryl.sutton@uspto.gov Date: 2007.09.12 15:58:59 -04'00'	Date Considered	09/12/2007
--------------------	------------------	---	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/824607
		Filing Date	2
		First Named Inventor	
		Group Art Unit	
		Examiner Name	Darryl Sutton
		Attorney Docket Number	102258.288
Sheet	7	of	7

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/D.S./		Carson et al, Journal of Cardiac Failure, 5(3):178-187 (September 10, 1999).	
/D.S./		Dries et al, The New England Journal of Medicine, 340(8):609-616 (February 25, 1999).	
/D.S./		Freedman et al, Drugs, 54 (Supplement 3):41-50 (1997).	
/D.S./		Sherman et al, Cardiologia, 42(2):177-187 (1997).	
/D.S./		Biegelson et al, Coronary Artery Disease, 10:241-256 (1999).	
/D.S./		Rudd et al, Am. J. Physiol., 277(46):H732-H739 (1999).	
/D.S./		Hammerman et al, Am. J. Physiol., 277(46):H1579-1592 (1999).	
/D.S./		Loscalzo et al, Transactions of the American and Climatological Ass., 111:158-163 (2000).	
/D.S./		Dupuis, Cardiovascular Drugs and Therapy, 8(3):501-507 (1994).	

Examiner Signature	Darryl C. Sutton	Digitally signed by Darryl C. Sutton DN: cn=Darryl C. Sutton, c=US, o=USPTO, email=darryl.sutton@uspto.gov Date: 2007.09.12 15:59:21 -0400	Date Considered	09/12/2007
--------------------	------------------	---	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.